Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Gastroenterology Reports
Erschienen in: Current Gastroenterology Reports 12/2020

01.12.2020 | Endoscopy and Surgery (S Komanduri, Section Editor)

Endobariatrics and Metabolic Endoscopy: Can We Solve the Obesity Epidemic with Our Scope?

verfasst von: Jad Farha, Shahem Abbarh, Zadid Haq, Mohamad I. Itani, Andreas Oberbach, Vivek Kumbhari, Dilhana Badurdeen

Erschienen in: Current Gastroenterology Reports | Ausgabe 12/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Obesity is a chronic relapsing disease that results in cardiovascular disease, diabetes mellitus, and non-alcoholic fatty liver disease. Currently, surgery represents the most effective treatment. However, the advent of minimally invasive endoscopic bariatric therapy (EBT) has shifted the treatment paradigm to less invasive, cost-effective procedures with minimal complications and recovery time that are preferred by patients. In this review, we will describe current and future EBTs, focusing on outcomes and safety.

Recent Findings

The endoscope has provided an incisionless portal into the gastrointestinal tract for placement of space-occupying devices and intraluminal procedures. EBTs are no longer solely manipulating anatomic alterations; instead, they aim to improve metabolic parameters such as glycated hemoglobin, low-density lipoprotein, cholesterol, and hepatic indices by targeting the mucosal layer of the gastrointestinal tract.

Summary

The endoscope has succeeded in facilitating clinically meaningful weight loss and improvement of metabolic parameters. Future, solutions to the obesity epidemic will likely entail genetic testing, evaluation of the microbiome, and delivery of personalized therapy, utilizing combination endoscopic modalities that change the anatomy and physiology of individual patients, with new targets such as the abnormal metabolic signal.
Literatur
1.
Mason EE, Ito C. Gastric bypass in obesity. 1967. Obes Res. 1996;4(3):316–9.PubMed
2.
Alden JF. Gastric and jejunoileal bypass. A comparison in the treatment of morbid obesity. Arch Surg. 1977;112(7):799–806.PubMed
3.
Griffen WO Jr, Young VL, Stevenson CC. A prospective comparison of gastric and jejunoileal bypass procedures for morbid obesity. Ann Surg. 1977;186(4):500–9.PubMedPubMedCentral
4.
Fung M, Wharton S, Macpherson A, Kuk JL. Receptivity to bariatric surgery in qualified patients. J Obes. 2016;2016:5372190.PubMedPubMedCentral
5.
Ginsberg GG, Chand B, Cote GA, Dallal RM, Edmundowicz SA, Nguyen NT, et al. A pathway to endoscopic bariatric therapies. Gastrointest Endosc. 2011;74(5):943–53.PubMed
6.
Gómez V. Making a U-turn at the stomach. Gastrointest Endosc. 2019;90(5):781–3.PubMed
7.
Abu Dayyeh BK, Acosta A, Camilleri M, Mundi MS, Rajan E, Topazian MD, et al. Endoscopic sleeve gastroplasty alters gastric physiology and induces loss of body weight in obese individuals. Clin Gastroenterol Hepatol. 2017;15(1):37–43.e1.PubMed
8.
Lopez-Nava G, Sharaiha RZ, Vargas EJ, Bazerbachi F, Manoel GN, Bautista-Castano I, et al. Endoscopic sleeve gastroplasty for obesity: a multicenter study of 248 patients with 24 months follow-up. Obes Surg. 2017;27(10):2649–55.PubMed
9.
Alqahtani A, Al-Darwish A, Mahmoud AE, Alqahtani YA, Elahmedi M. Short-term outcomes of endoscopic sleeve gastroplasty in 1000 consecutive patients. Gastrointest Endosc. 2019;89(6):1132–8.PubMed
10.
Barrichello S, Hourneaux de Moura DT, Hourneaux de Moura EG, Jirapinyo P, Hoff AC, Fittipaldi-Fernandez RJ, et al. Endoscopic sleeve gastroplasty in the management of overweight and obesity: an international multicenter study. Gastrointest Endosc. 2019;90(5):770–80.PubMed
11.
Sartoretto A, Sui Z, Hill C, Dunlap M, Rivera AR, Khashab MA, et al. Endoscopic sleeve gastroplasty (ESG) is a reproducible and effective endoscopic bariatric therapy suitable for widespread clinical adoption: a large. Int Multicenter Study Obes Surg. 2018;28(7):1812–21.
12.
James TW, Reddy S, Vulpis T, McGowan CE. Endoscopic sleeve gastroplasty is feasible, safe, and effective in a non-academic setting: short-term outcomes from a community gastroenterology practice. Obes Surg. 2020;30(4):1404–9.PubMed
13.
Graus Morales J, Crespo Perez L, Marques A, Marin Arribas B, Bravo Arribas R, Ramo E, et al. Modified endoscopic gastroplasty for the treatment of obesity. Surg Endosc. 2018;32(9):3936–42.PubMed
14.
Lopez-Nava G, Galvao MP, Bautista-Castano I, Fernandez-Corbelle JP, Trell M, Lopez N. Endoscopic sleeve gastroplasty for obesity treatment: two years of experience. Arq Bras Cir Dig. 2017;30(1):18–20.PubMedPubMedCentral
15.
Hedjoudje A, Dayyeh BA, Cheskin LJ, Adam A, Neto MG, Badurdeen D, et al. Efficacy and safety of endoscopic sleeve gastroplasty: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2019.
16.
Singh S, de Moura DTH, Khan A, Bilal M, Ryan MB, Thompson CC. Safety and efficacy of endoscopic sleeve gastroplasty worldwide for treatment of obesity: a systematic review and meta-analysis. Surg Obes Relat Dis. 2020;16(2):340–51.PubMed
17.
Itani MI, Farha J, Marrache MK, Fayad L, Badurdeen D, Kumbhari V. The effects of bariatric surgery and endoscopic bariatric therapies on GERD: an update. Curr Treat Options Gastroenterol. 2020;18:97–108.
18.
Runge TM, Yang J, Fayad L, Itani MI, Dunlap M, Koller K, et al. Correction to: anatomical configuration of the stomach post-endoscopic sleeve gastroplasty (ESG)-what are the sutures doing? Obes Surg. 2020;30(5):2061.PubMed
19.
Hajifathalian K, Ang B, Dawod QM, Shah SL, Dawod E, Mehta A, et al. 175 Long-term follow up and outcomes after endoscopic sleeve gastroplasty for treatment of obesity (5 year data). Gastrointest Endosc. 2019;89(6):AB58.
20.
Fayad L, Cheskin LJ, Adam A, Badurdeen DS, Hill C, Agnihotri A, et al. Endoscopic sleeve gastroplasty versus intragastric balloon insertion: efficacy, durability, and safety. Endoscopy. 2019;51(6):532–9.PubMed
21.
Cheskin LJ, Hill C, Adam A, Fayad L, Dunlap M, Badurdeen D, et al. Endoscopic sleeve gastroplasty versus high-intensity diet and lifestyle therapy: a case-matched study. Gastrointest Endosc. 2020;91(2):342–9.e1.PubMed
22.
Fayad L, Adam A, Schweitzer M, Cheskin LJ, Ajayi T, Dunlap M, et al. Endoscopic sleeve gastroplasty versus laparoscopic sleeve gastrectomy: a case-matched study. Gastrointest Endosc. 2019;89(4):782–8.PubMed
23.
Badurdeen DS, Kumbhari V. Endoscopic sleeve gastroplasty and its application to China. J Dig Dis. 2017;18(10):551–5.PubMed
24.
Sharaiha RZ, Kumta NA, Saumoy M, Desai AP, Sarkisian AM, Benevenuto A, et al. Endoscopic sleeve gastroplasty significantly reduces body mass index and metabolic complications in obese patients. Clin Gastroenterol Hepatol. 2017;15(4):504–10.PubMed
25.
López-Nava G, Bautista-Castaño I, Jimenez A, De Grado T, Fernandez-Corbelle JP. The Primary Obesity Surgery Endolumenal (POSE) procedure: one-year patient weight loss and safety outcomes. Surg Obes Relat Dis. 2015;11(4):861–5.PubMed
26.
Jirapinyo P, Thompson CC. Gastric plications for weight loss: distal primary obesity surgery endoluminal through a belt-and-suspenders approach. VideoGIE. 2018;3(10):296–300.PubMedPubMedCentral
27.
Jirapinyo P, Thompson CC. Endoscopic gastric body plication for the treatment of obesity: technical success and safety of a novel technique (with video). Gastrointest Endosc. 2020;91(6):1388–94.PubMed
28.
Lopez-Nava G, Asokkumar R, Turró Arau R, Neto MG, Dayyeh BA. Modified primary obesity surgery endoluminal (POSE-2) procedure for the treatment of obesity. VideoGIE. 2020;5(3):91–3.PubMedPubMedCentral
29.
Espinós J, Turró R, Mata A, Cruz M, Da Costa M, Villa V, et al. Early experience with the Incisionless Operating Platform™(IOP) for the treatment of obesity. Obes Surg. 2013;23(9):1375–83.PubMed
30.
Sullivan S, Swain JM, Woodman G, Antonetti M, De La Cruz-Muñoz N, Jonnalagadda SS, et al. Randomized sham-controlled trial evaluating efficacy and safety of endoscopic gastric plication for primary obesity: the ESSENTIAL trial. Obesity (Silver Spring). 2017;25(2):294–301.
31.
Lerner H, Whang J, Nipper R. Benefit-risk paradigm for clinical trial design of obesity devices: FDA proposal. Surg Endosc. 2013;27(3):702–7.PubMed
32.
Miller K, Turró R, Greve JW, Bakker CM, Buchwald JN, Espinós JC. MILEPOST multicenter randomized controlled trial: 12-month weight loss and satiety outcomes after pose (SM) vs. Med Ther Obes Surg. 2017;27(2):310–22.
33.
Espinós JC, Turró R, Moragas G, Bronstone A, Buchwald JN, Mearin F, et al. Gastrointestinal physiological changes and their relationship to weight loss following the POSE procedure. Obes Surg. 2016;26(5):1081–9.PubMed
34.
Kumar N, Sullivan S, Thompson CC. The role of endoscopic therapy in obesity management: intragastric balloons and aspiration therapy. Diabetes Metab Syndr Obes. 2017;10:311–6.PubMedPubMedCentral
35.
Barrichello S, Badurdeen D, Hedjoudje A, Neto MG, Yance R, Veinert A, et al. The effect of the intra-gastric balloon on gastric emptying and the DeMeester score. Obes Surg. 2020;30(1):38–45.PubMed
36.
37.
Agnihotri A, Xie A, Bartalos C, Kushnir V, Sullivan S, Islam S, et al. Real-world safety and efficacy of fluid-filled dual intragastric balloon for weight loss. Clin Gastroenterol Hepatol. 2018;16(7):1081–8.e1.PubMed
38.
39.
Neto MG, Silva LB, Grecco E, de Quadros LG, Teixeira A, Souza T, et al. Brazilian intragastric balloon consensus statement (BIBC): practical guidelines based on experience of over 40,000 cases. Surg Obes Relat Dis. 2018;14(2):151–9.PubMed
40.
Ball W, Raza SS, Loy J, Riera M, Pattar J, Adjepong S, et al. Effectiveness of intra-gastric balloon as a bridge to definitive surgery in the super obese. Obes Surg. 2019;29(6):1932–6.PubMed
41.
42.
Dayyeh BKA, Eaton LL, Woodman G, Fusco M, Shayani V, Billy HT, et al. 444 a randomized, multi-center study to evaluate the safety and effectiveness of an intragastric balloon as an adjunct to a behavioral modification program, in comparison with a behavioral modification program alone in the weight management of obese subjects. Gastrointest Endosc. 2015;81(5):AB147.
43.
Abu Dayyeh BK, Kumar N, Edmundowicz SA, Jonnalagadda S, Larsen M, Sullivan S, et al. ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc. 2015;82(3):425–38.e5.PubMed
44.
Kotzampassi K, Grosomanidis V, Papakostas P, Penna S, Eleftheriadis E. 500 intragastric balloons: what happens 5 years thereafter? Obes Surg. 2012;22(6):896–903.PubMed
45.
46.
Dumonceau JM, Francois E, Hittelet A, Mehdi AI, Barea M, Deviere J. Single vs repeated treatment with the intragastric balloon: a 5-year weight loss study. Obes Surg. 2010;20(6):692–7.PubMed
47.
Genco A, Cipriano M, Bacci V, Maselli R, Paone E, Lorenzo M, et al. Intragastric balloon followed by diet vs intragastric balloon followed by another balloon: a prospective study on 100 patients. Obes Surg. 2010;20(11):1496–500.PubMed
48.
Mitura K, Garnysz K. Tolerance of intragastric balloon and patient’s satisfaction in obesity treatment. Wideochir Inne Tech Maloinwazyjne. 2015;10(3):445–9.PubMedPubMedCentral
49.
Barola S, Agnihotri A, Chang Chiu A, Kalloo AN, Kumbhari V. Spontaneous hyperinflation of an Intragastric balloon 5 months after insertion. Am J Gastroenterol. 2017;112(3):412.PubMed
50.
Fayad L, Simsek C, Khashab MA, Kalloo AN, Kumbhari V. Gastrointestinal: Intragastric balloon: gastric outlet obstruction or resting in the antrum? J Gastroenterol Hepatol. 2019;34(1):8.PubMed
51.
52.
Bazerbachi F, Vargas EJ, Rizk M, Maselli DB, Mounajjed T, Venkatesh SK, et al. Intragastric balloon placement induces significant metabolic and histologic improvement in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2020;S1542-3565(20)30613–3. https://​doi.​org/​10.​1016/​j.​cgh.​2020.​04.​068.
53.
54.
Sullivan S, Swain J, Woodman G, Edmundowicz S, Hassanein T, Shayani V, et al. Randomized sham-controlled trial of the 6-month swallowable gas-filled intragastric balloon system for weight loss. Surg Obes Relat Dis. 2018;14(12):1876–89.PubMed
55.
Bazerbachi F, Haffar S, Sawas T, Vargas EJ, Kaur RJ, Wang Z, et al. Fluid-filled versus gas-filled intragastric balloons as obesity interventions: a network meta-analysis of randomized trials. Obes Surg. 2018;28(9):2617–25.PubMed
56.
Brooks J, Srivastava ED, Mathus-Vliegen EM. One-year adjustable intragastric balloons: results in 73 consecutive patients in the U.K. Obes Surg. 2014;24(5):813–9.PubMed
57.
Russo T, Aprea G, Formisano C, Ruggiero S, Quarto G, Serra R, et al. BioEnterics Intragastric Balloon (BIB) versus Spatz adjustable balloon system (ABS): our experience in the elderly. Int J Surg. 2017;38:138–40.PubMed
58.
Machytka E, Divi VP, Saenger F, Sorio R, Brooks J. Mo1296a adjustable balloons for weight loss: a higher yield of responders compared with non-adjustable balloons. Gastrointest Endosc. 2017;85(5):AB495.
59.
Usuy E, Brooks J. Response rates with the Spatz3 adjustable balloon. Obes Surg. 2018;28(5):1271–6.PubMed
60.
61.
Thompson CC, Dayyeh BKA, Kushner R, Sullivan S, Schorr AB, Amaro A, et al. Percutaneous gastrostomy device for the treatment of class II and class III obesity: results of a randomized controlled trial. Am J Gastroenterol. 2017;112(3):447–57.PubMed
62.
Thompson CC, Abu Dayyeh BK, Kushnir V, Kushner RF, Jirapinyo P, Schorr AB, et al. Aspiration therapy for the treatment of obesity: 4-year results of a multicenter randomized controlled trial. Surg Obes Relat Dis. 2019;15(8):1348–54.PubMed
63.
64.
Kumbhari V, Okolo PI III. Editorial: aspiration therapy for weight loss: is the squeeze worth the juice? Am J Gastroenterol. 2017;112(3):458–589.PubMed
65.
Gjeorgjievski M, Reddy N, Stecevic V, Cappell MS. Abdominal abscess related to endoscopically placed AspireAssist® device. ACG Case Rep J. 2018;5:e12.PubMedPubMedCentral
66.
67.
Marinos G, Eliades C, Muthusam VR, Greenway F. Weight loss and improved quality of life with a nonsurgical endoscopic treatment for obesity: clinical results from a 3- and 6-month study. Surg Obes Relat Dis. 2014;10(5):929–34.PubMed
68.
Rothstein R, Woodman G, Swain J, Cruz NDL, Kushnir V, Pryor A, et al. Transpyloric shuttle treatment improves cardiometabolic risk factors and quality of life in patients with obesity: results from a randomized, double-blind, Sham-Controlled Trial. Gastroenterology. 2019;156(6):S-237.
69.
Park J, Bakheet N, Na H, Jeon J, Yoon S, Kim K, et al. A novel full sense device to treat obesity in a porcine model: preliminary results. Obes Surg. 2019;29(5):1521–7.PubMed
70.
Luo Y, Zhang X, Tsauo J, Jung H, Song H, Zhao H, et al. Intragastric satiety-inducing device reduces food intake and suppresses body weight gain in a rodent model. Surg Endosc. 2020;24:1–6.
71.
Sjöström L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351(26):2683–93.PubMed
72.
Thaler JP, Cummings DE. Minireview: hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery. Endocrinology. 2009;150(6):2518–25.PubMed
73.
Breen DM, Rasmussen BA, Kokorovic A, Wang R, Cheung GW, Lam TK. Jejunal nutrient sensing is required for duodenal-jejunal bypass surgery to rapidly lower glucose concentrations in uncontrolled diabetes. Nat Med. 2012;18(6):950–5.PubMed
74.
Rodriguez L, Reyes E, Fagalde P, Oltra MS, Saba J, Aylwin CG, et al. Pilot clinical study of an endoscopic, removable duodenal-jejunal bypass liner for the treatment of type 2 diabetes. Diabetes Technol Ther. 2009;11(11):725–32.PubMed
75.
Koehestanie P, de Jonge C, Berends FJ, Janssen IM, Bouvy ND, Greve JW. The effect of the endoscopic duodenal-jejunal bypass liner on obesity and type 2 diabetes mellitus, a multicenter randomized controlled trial. Ann Surg. 2014;260(6):984–92.PubMed
76.
de Moura EG, Martins BC, Lopes GS, Orso IR, de Oliveira SL, Galvão Neto MP, et al. Metabolic improvements in obese type 2 diabetes subjects implanted for 1 year with an endoscopically deployed duodenal-jejunal bypass liner. Diabetes Technol Ther. 2012;14(2):183–9.PubMed
77.
Rohde U, Hedbäck N, Gluud LL, Vilsbøll T, Knop FK. Effect of the EndoBarrier gastrointestinal liner on obesity and type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2016;18(3):300–5.PubMed
78.
79.
Betzel B, Drenth JP, Siersema PD. Adverse events of the duodenal-jejunal bypass liner: a systematic review. Obes Surg. 2018;28(11):3669–77.PubMed
80.
Sandler BJ, Rumbaut R, Swain CP, Torres G, Morales L, Gonzales L, et al. One-year human experience with a novel endoluminal, endoscopic gastric bypass sleeve for morbid obesity. Surg Endosc. 2015;29(11):3298–303.PubMed
81.
82.
Badurdeen DS, Fayad L, Kalloo AN, Kumbhari V. The forgotten fundus-response to - obesity treatment with botulinum toxin-a is not effective: a systematic review and meta-analysis. Obes Surg. 2018;28(1):262–3.PubMed
83.
Bustamante F, Brunaldi VO, Bernardo WM, de Moura DTH, de Moura ETH, Galvão M, et al. Obesity treatment with botulinum toxin-a is not effective: a systematic review and meta-analysis. Obes Surg. 2017;27(10):2716–23.PubMed
84.
Foschi D, Corsi F, Lazzaroni M, Sangaletti O, Riva P, La Tartara G, et al. Treatment of morbid obesity by intraparietogastric administration of botulinum toxin: a randomized, double-blind, controlled study. Int J Obes. 2007;31(4):707–12.
85.
86.
Cherrington AD, Rajagopalan H, Maggs D, Devière J. Hydrothermal duodenal mucosal resurfacing: role in the treatment of metabolic disease. Gastrointest Endosc Clin. 2017;27(2):299–311.
87.
Rajagopalan H, Cherrington AD, Thompson CC, Kaplan LM, Rubino F, Mingrone G, et al. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes: 6-month interim analysis from the first-in-human proof-of-concept study. Diabetes Care. 2016;39(12):2254–61.PubMed
88.
van Baar AC, Holleman F, Crenier L, Haidry R, Magee C, Hopkins D, et al. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: one year results from the first international, open-label, prospective, multicentre study. Gut. 2020;69(2):295–303.PubMed
89.
van Baar AC, Beuers U, Wong K, Haidry R, Costamagna G, Hafedi A, et al. Endoscopic duodenal mucosal resurfacing improves glycaemic and hepatic indices in type 2 diabetes: 6-month multicentre results. JHEP Rep. 2019;1(6):429–37.PubMedPubMedCentral
90.
Machytka E, Bužga M, Zonca P, Lautz DB, Ryou M, Simonson DC, et al. Partial jejunal diversion using an incisionless magnetic anastomosis system: 1-year interim results in patients with obesity and diabetes. Gastrointest Endosc. 2017;86(5):904–12.PubMed
91.
Ryou M, Agoston AT, Thompson CC. Endoscopic intestinal bypass creation by using self-assembling magnets in a porcine model. Gastrointest Endosc. 2016;83(4):821–5.PubMed
92.
Kluge F, Seidler E. First use of Osophago and gastroscopy: letters from Adolf Kussmaul and his staff. Med J. 1986;21(3–4):288–307.
93.
Hirschowitz BI, Curtiss LE, Peters CW, Pollard HM. Demonstration of a new gastroscope, the fiberscope. Gastroenterology. 1958;35(1):50; discussion 1-3–3.PubMed
94.
Sivak MV Jr, Fleischer DE. Colonoscopy with a videoendoscope: preliminary experience. Gastrointest Endosc. 1984;30(1):1–5.PubMed
95.
Fayad L, Oberbach A, Schweitzer M, Askin F, Voltaggio L, Larman T, et al. Gastric mucosal devitalization (GMD): translation to a novel endoscopic metabolic therapy. Endosc Int Open. 2019;7(12):E1640–e5.PubMedPubMedCentral
96.
Kumbhari V, Lehmann S, Schlichting N, Heinrich M, Kullnick Y, Retschlag U, et al. Gastric mucosal devitalization is safe and effective in reducing body weight and visceral adiposity in a porcine model. Gastrointest Endosc. 2018;88(1):175–84.e1.PubMed
97.
Oberbach A, Schlichting N, Heinrich M, Kullnick Y, Retschlag U, Lehmann S, et al. Gastric mucosal devitalization reduces adiposity and improves lipid and glucose metabolism in obese rats. Gastrointest Endosc. 2018;87(1):288–99.e6.PubMed
98.
Kelly CR, Khoruts A, Staley C, Sadowsky MJ, Abd M, Alani M, et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: a randomized trial. Ann Intern Med. 2016;165(9):609–16.PubMedPubMedCentral
99.
Youngster I, Sauk J, Pindar C, Wilson RG, Kaplan JL, Smith MB, et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis. 2014;58(11):1515–22.PubMedPubMedCentral
100.
Van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407–15.PubMed
101.
Choi HH, Cho Y-S. Fecal microbiota transplantation: current applications, effectiveness, and future perspectives. Clin Endosc. 2016;49(3):257–65.PubMedPubMedCentral
102.
Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143(4):913–6. e7.PubMed
103.
104.
105.
106.
Silverman M. Transplantation of microbes for treatment of metabolic syndrome and NAFLD (FMT). NihGov, vol NCT02496390. 2016.
Metadaten
Titel
Endobariatrics and Metabolic Endoscopy: Can We Solve the Obesity Epidemic with Our Scope?
verfasst von
Jad Farha
Shahem Abbarh
Zadid Haq
Mohamad I. Itani
Andreas Oberbach
Vivek Kumbhari
Dilhana Badurdeen
Publikationsdatum
01.12.2020
Verlag
Springer US
Erschienen in
Current Gastroenterology Reports / Ausgabe 12/2020
Print ISSN: 1522-8037
Elektronische ISSN: 1534-312X
DOI
https://doi.org/10.1007/s11894-020-00798-8

Weitere Artikel der Ausgabe 12/2020

Current Gastroenterology Reports 12/2020 Zur Ausgabe

Endoscopy and Surgery (S Komanduri, Section Editor)

Advances in Biliary Access

Inflammatory Bowel Disease (M Regueiro, Section Editor)

Inflammatory Bowel Disease Environmental Risk Factors: Diet and Gut Microbiota

Endoscopy and Surgery (S Komanduri, Section Editor)

Determining the Indeterminate Biliary Stricture: Cholangioscopy and Beyond

Liver (Scott C and E Kallwitz, Section Editors)

Causes and Management of Non-cirrhotic Portal Hypertension​

Endoscopy and Surgery (S Komanduri, Section Editor)

Emerging Therapies to Prevent Post-ERCP Pancreatitis

Endoscopy and Surgery (S Komanduri, Section Editor)

Endoscopic Eradication Therapy for Barrett’s Neoplasia: Where Do We Stand a Decade Later?

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise